Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28773196 | 0.91 | KDM4E (0.58) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL25308843 | 0.87 | KDM4E (0.65) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL28548612 | 0.82 | ALDH1A1 (0.48) | KDM4ESMN1; SMN2ALDH1A1MAPTLMNA | |
| SCHEMBL1801810 | 0.80 | CD274 (0.62) | KDM4ESMN1; SMN2ALDH1A1EPHX2GAA | |
| SCHEMBL28885280 | 0.79 | MAPT (0.61) | SMN1; SMN2ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL1600161 | 0.79 | BRD4 (0.49) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL21588984 | 0.79 | MAPT (0.55) | KDM4ESMN1; SMN2ALDH1A1MAPTLMNA | |
| SCHEMBL1663955 | 0.78 | KDM4E (0.71) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL28538284 | 0.77 | GAA (0.60) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL1605174 | 0.77 | KDM4E (0.74) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090816-A1 | ANTI-INFECTIVE BIARYL COMPOUNDS | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-7265129-B2 | Anti-infective biaryl compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090816-A1 | ANTI-INFECTIVE BIARYL COMPOUNDS | QTRT1, Q6ZSR9, QTRT2 | KDM4E 3096/4885SMN1; SMN2 4635/4885ALDH1A1 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.